Lantheus Holdings, Inc.（简称Lantheus）近日宣布，美国食品药品监督管理局（FDA）已正式批准其新药Tauklarify™（Florquinitau F 18 Injection，即氟喹他F18注射液）。该药物是一种采用F18标记的tau蛋白正电子发射断层扫描（PET）成像试剂，专门用于阿尔茨海默病的诊断与评估。
Lantheus Holdings, Inc.（简称Lantheus）近日宣布，美国食品药品监督管理局（FDA）已正式批准其新药Tauklarify™（Florquinitau F 18 Injection，即氟喹他F18注射液）。该药物是一种采用F18标记的tau蛋白正电子发射断层扫描（PET）成像试剂，专门用于阿尔茨海默病的诊断与评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.